The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide for weight loss following safety concerns.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,